DE69636308T2 - Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe - Google Patents

Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe Download PDF

Info

Publication number
DE69636308T2
DE69636308T2 DE69636308T DE69636308T DE69636308T2 DE 69636308 T2 DE69636308 T2 DE 69636308T2 DE 69636308 T DE69636308 T DE 69636308T DE 69636308 T DE69636308 T DE 69636308T DE 69636308 T2 DE69636308 T2 DE 69636308T2
Authority
DE
Germany
Prior art keywords
alkyl
tnf
hydrogen
use according
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69636308T
Other languages
German (de)
English (en)
Other versions
DE69636308D1 (de
Inventor
Esther Shohami
Ruth Gallily
Raphael Mechoulam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of DE69636308D1 publication Critical patent/DE69636308D1/de
Publication of DE69636308T2 publication Critical patent/DE69636308T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69636308T 1995-09-11 1996-09-10 Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe Expired - Fee Related DE69636308T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11524595 1995-09-11
IL11524595A IL115245A (en) 1995-09-11 1995-09-11 Tumor necrosis factor inhibiting pharmaceuticals
PCT/IL1996/000108 WO1997011668A2 (en) 1995-09-11 1996-09-10 TUMOR NECROSIS FACTOR ALPHA (TNF-α) INHIBITING PHARMACEUTICALS

Publications (2)

Publication Number Publication Date
DE69636308D1 DE69636308D1 (de) 2006-08-10
DE69636308T2 true DE69636308T2 (de) 2007-05-31

Family

ID=11067971

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636308T Expired - Fee Related DE69636308T2 (de) 1995-09-11 1996-09-10 Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe

Country Status (9)

Country Link
US (3) US5932610A (OSRAM)
EP (1) EP0876143B1 (OSRAM)
JP (1) JP2000500737A (OSRAM)
AT (1) ATE331503T1 (OSRAM)
AU (1) AU708886B2 (OSRAM)
CA (1) CA2231764A1 (OSRAM)
DE (1) DE69636308T2 (OSRAM)
IL (1) IL115245A (OSRAM)
WO (1) WO1997011668A2 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US20010009965A1 (en) * 1998-05-04 2001-07-26 Alexandros Makriyannis Novel analgesic and immunomodulatory cannabinoids
US7589220B2 (en) * 1998-06-09 2009-09-15 University Of Connecticut Inhibitors of the anandamide transporter
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US7276613B1 (en) 1998-11-24 2007-10-02 University Of Connecticut Retro-anandamides, high affinity and stability cannabinoid receptor ligands
US7161016B1 (en) 1998-11-24 2007-01-09 University Of Connecticut Cannabimimetic lipid amides as useful medications
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
AU3910700A (en) 1999-03-22 2000-10-09 Immugen Pharmaceuticals, Inc. Treatment of immune diseases
DE60033834T2 (de) 1999-10-18 2007-11-15 The University Of Connecticut, Farmington Für periphäre cannabinoid-rezeptoren selektive liganden
US6943266B1 (en) 1999-10-18 2005-09-13 University Of Connecticut Bicyclic cannabinoid agonists for the cannabinoid receptor
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US6900236B1 (en) * 1999-10-18 2005-05-31 University Of Connecticut Cannabimimetic indole derivatives
US8084467B2 (en) * 1999-10-18 2011-12-27 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7741365B2 (en) * 1999-10-18 2010-06-22 University Of Connecticut Peripheral cannabinoid receptor (CB2) selective ligands
US7393842B2 (en) * 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6531128B1 (en) * 2000-02-08 2003-03-11 Pharmacia Corporation Methods for treating glaucoma
JP2003529561A (ja) * 2000-02-08 2003-10-07 ワックス、マーティン、ビー 緑内障の治療法
AU2001259691B2 (en) 2000-05-12 2006-02-16 Genzyme Corporation Modulators of TNF-alpha signaling
US7235584B2 (en) * 2000-06-22 2007-06-26 Pharmos Corporation Non-psychotropic cannabinoids
KR20030008153A (ko) * 2000-06-22 2003-01-24 파모스 코포레이션 신규 비-향정신성 카나비노이드
EP1785417A3 (en) * 2000-06-22 2007-08-01 Pharmos Corporation Novel non-psychotropic cannabinoids
WO2002026728A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
WO2002026224A2 (en) * 2000-09-28 2002-04-04 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
WO2002058636A2 (en) * 2001-01-26 2002-08-01 University Of Connecticut Novel cannabimimetic ligands
EP1363632B1 (en) 2001-01-29 2010-08-25 The University of Connecticut Receptor selective cannabimimetic aminoalkylindoles
ES2706902T3 (es) 2001-06-26 2019-04-01 Amgen Inc Anticuerpos para OPGL
EP1414775B1 (en) * 2001-07-13 2012-12-19 The University of Connecticut Bicyclic cannabinoid
US7666867B2 (en) * 2001-10-26 2010-02-23 University Of Connecticut Heteroindanes: a new class of potent cannabimimetic ligands
WO2003080043A1 (en) * 2002-03-18 2003-10-02 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
US20050137251A1 (en) * 2002-03-18 2005-06-23 Aaron Garzon Dexanabinol and dexanabinol analogs regulate inflammation related genes
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes
JP2006511460A (ja) 2002-08-23 2006-04-06 ユニバーシティ オブ コネチカット 治療適応を持つケトカンナビノイド
US20050192341A1 (en) * 2002-09-05 2005-09-01 Seth Kindler Non-psychotropic cannabinoids for prevention of cognitive impairment
ES2363914T3 (es) * 2002-11-21 2011-08-19 Genzyme Corporation Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
WO2004047826A1 (en) * 2002-11-21 2004-06-10 Genzyme Corporation Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
AU2003302578A1 (en) * 2002-12-04 2004-06-23 Pharmos Corporation High enantiomeric purity dexanabinol for pharmaceutical compositions
EP2578577A1 (en) 2005-09-29 2013-04-10 Albany Molecular Research, Inc. Sulfonyl esters of tetrahydrocannabinol and derivatives thereof
WO2009059277A1 (en) * 2007-11-02 2009-05-07 University Of South Florida Synergistic modulation of microglial activation by nicotine and thc
GB0915877D0 (en) 2009-09-10 2009-10-14 E Therapeutics Plc Cancer cell apoptosis
GB201207305D0 (en) 2012-04-26 2012-06-13 E Therapeutics Plc Therapy
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80411A (en) * 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
US5284867A (en) * 1989-11-07 1994-02-08 Yissum Research Development Company Of The Hebrew University In Jerusalem NMDA-blocking pharmaceutical compositions
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
WO1994012667A1 (en) * 1992-11-27 1994-06-09 The United States Department Of The Army Inhibitors of arachidonic acid metabolites for preventing neurological damage

Also Published As

Publication number Publication date
AU708886B2 (en) 1999-08-12
US20020049245A1 (en) 2002-04-25
JP2000500737A (ja) 2000-01-25
DE69636308D1 (de) 2006-08-10
EP0876143A4 (en) 2001-06-27
US5932610A (en) 1999-08-03
EP0876143A2 (en) 1998-11-11
IL115245A0 (en) 1995-12-31
US6545041B2 (en) 2003-04-08
EP0876143B1 (en) 2006-06-28
US6331560B1 (en) 2001-12-18
WO1997011668A3 (en) 1997-05-15
WO1997011668A2 (en) 1997-04-03
CA2231764A1 (en) 1997-04-03
ATE331503T1 (de) 2006-07-15
IL115245A (en) 2002-12-01
AU6942096A (en) 1997-04-17

Similar Documents

Publication Publication Date Title
DE69636308T2 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
DE69923671T2 (de) Verwendung von cannabidiol als entzündunghemmende mittel
DE60125541T2 (de) Neue nicht psychotropische cannabinoide
DE69822665T2 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69621603T2 (de) Behandlung von cerebraler ischämie und cerebralen verletzungen mit nervenschutzmitteln
DE69529156T2 (de) Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit
DE69232016T2 (de) Pharmazeutische zusammensetzung, die gamma-hydroxybuttersäure oder das entsprechende lakton enthält, zur behandlung von drogenabhängigkeit und ernährungsstörungen
EP0501205B1 (de) Antiphlogistisches Mittel
DE60106026T2 (de) 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen
DE3390116C2 (de) Verbesserte, Koffein enthaltende, analgetische und antiinflammatorische Mittel
DE3511609C2 (OSRAM)
DE69522578T2 (de) Glial neurotropher faktor als nervenschutzmittel
DE3390114T1 (de) Verbesserte analgetische und antiinflammatorische, Ibuprofen enthaltende Zubereitungen und Verfahren zu ihrer Herstellung
EP0267404B1 (de) Dermale Behandlung von Wurmerkrankungen der Katze mit Praziquantel
DE60020111T2 (de) Therapeutische anwendung von cannabinoiden zur hirntumorbehandlung
DE69017839T2 (de) NMDA-blockierende Verbindungen, pharmazeutische Präparate, deren Herstellung und Verwendung.
WO1993012784A1 (de) Bilobalid enthaltende pharmazeutische zubereitungen zur behandlung von spannungs- und angstzuständen
EP1154776B1 (de) Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus
DE69326188T2 (de) Verwendung von N-Acylderivaten von Aminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von neurogenen endoneuralen Ödemen der peripheren Nerven
EP1834640A2 (de) Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
DE3723248A1 (de) Verwendung von thiosulfinsaeurederivaten zur behandlung von entzuendungserkrankungen
WO2004082699A2 (de) Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischämie und/oder schädel/hirntrauma
DE1767666C3 (de) Pharmazeutische Zubereitung gegen Lebererkrankungen
DE69904206T2 (de) Verwendung von cetirizin zur vorbeugung von asthma eintritt
LU601121B1 (de) Die Anwendung von β-roten Myrcen in Arzneimitteln zur Vorbeugung und Verbesserung von akuten Leberschäden

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee